Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.

Advances in enzyme regulation - 1 Jan 2011

Gabelli Sandra B, Duong-Ly Krisna C, Brower Evan T, Amzel L Mario

Abstract excerpt

PI3Ks catalyze the phosphorylation of the inositol hydroxyls of phosphoinositide membrane components. The changes in phosphorylation of the inositides recruit proteins to the plasma membrane that initiate important signaling cascades. PI3Kα, one of the class IA PI3Ks, is highly mutated in cancers...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Models, Molecular
Share to Neoplasms
Share to Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Protein Conformation

Share to Protein Kinase Inhibitors

Share to Protein Subunits

Source

Open in PubMed Open full text

Identifiers

PMID: 21035489
DOI: 10.1016/j.advenzreg.2010.09.013
PMCID: PMC3079044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21035489-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.PMID 21035489Read ↗

Structural effects of oncogenic PI3Kα mutations.Semantic proximity Read ↗

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.Semantic proximity Read ↗

A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.Semantic proximity Read ↗

Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.Semantic proximity Read ↗

Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.Semantic proximity Read ↗

The structural basis of PI3K cancer mutations: from mechanism to therapy.Semantic proximity Read ↗

Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.Semantic proximity Read ↗

Somatic mutations in PI3Kα: Structural basis for enzyme activation and drug designSemantic proximity Read ↗

The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Semantic proximity Read ↗

Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.Semantic proximity Read ↗

Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.Semantic proximity Read ↗

Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.